Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Podcast with Dr. Patricia Ganz about the quality of life results from the OlympiA trial
4. Datopotamab deruxtecan safe and effective in advanced or metastatic triple-negative breast cancer
5. Neratinib plus trastuzumab and fulvestrant for HER2-mutant, HR+ metastatic breast cancer